EOC Pharma, the Shanghai oncology arm of China company Eddingpharm, acquired greater China rights to an mTOR inhibitor from Los Angeles-based Aadi Bioscience. EOC signed a $271 million agreement consisting of upfront and milestone payments, plus royalties, for the rights. Aadi has submitted a US NDA for the candidate (ABI-009) to treat advanced malignant PEComa, a rare type of sarcoma. EOC Pharma combines independent R&D with in-licensings to build a portfolio of first- and best-in-class oncology drugs. More details.... Share this with colleagues: // //